These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30689078)

  • 41. Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients.
    Liu JY; Qian CY; Gao YF; Chen J; Zhou HH; Yin JY
    Chin J Cancer; 2017 Jan; 36(1):12. PubMed ID: 28093084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
    Shao M; Jin B; Niu Y; Ye J; Lu D; Han B
    Cell Biochem Biophys; 2014 Nov; 70(2):1227-37. PubMed ID: 24948471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population.
    Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
    Oncol Rep; 2021 Mar; 45(3):1295-1305. PubMed ID: 33469680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.
    Zhao X; Wang X; Wu W; Gao Z; Wu J; Garfield DH; Wang H; Wang J; Qian J; Li H; Jin L; Li Q; Han B; Lu D; Bai C
    Cancer; 2012 Jul; 118(14):3587-98. PubMed ID: 22072145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy.
    Zheng Y; Deng Z; Tang M; Cai P
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):495-502. PubMed ID: 33461346
    [No Abstract]   [Full Text] [Related]  

  • 46. Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
    Cao S; Wang S; Ma H; Tang S; Sun C; Dai J; Wang C; Shu Y; Xu L; Yin R; Song X; Chen H; Han B; Li Q; Wu J; Bai C; Chen J; Jin G; Hu Z; Lu D; Shen H
    Pharmacogenomics J; 2016 Feb; 16(1):41-6. PubMed ID: 25823687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.
    Yuan Z; Li J; Hu R; Jiao Y; Han Y; Weng Q
    Sci Rep; 2015 Nov; 5():16482. PubMed ID: 26585370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.
    Zhu N; Gong Y; He J; Xia J; Chen X
    Yonsei Med J; 2013 Nov; 54(6):1384-93. PubMed ID: 24142642
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
    Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
    Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
    Zhou F; Gao G; Ren S; Li X; He Y; Zhou C
    PLoS One; 2013; 8(4):e61585. PubMed ID: 23620771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
    Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
    Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.
    Singh A; Singh N; Behera D; Sharma S
    Mol Biol Rep; 2018 Jun; 45(3):253-261. PubMed ID: 29397516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.
    Xu X; Duan L; Zhou B; Ma R; Zhou H; Liu Z
    Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):786-92. PubMed ID: 22725681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of IL27 and STAT3 genetic polymorphism on the susceptibility of tuberculosis in Western Chinese Han population.
    Li M; Jiao L; Lyu M; Song J; Bai H; Zhang C; Wu T; Chen X; Ying B
    Infect Genet Evol; 2020 Sep; 83():104324. PubMed ID: 32320824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian patients treated with platinum-based doublet chemotherapy.
    Lawania S; Singh N; Behera D; Sharma S
    Future Oncol; 2019 Jan; 15(2):151-165. PubMed ID: 30522358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Zhang XR; Xu BH; Lin DX
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):196-9. PubMed ID: 16875604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic polymorphisms in the
    Walia HK; Singh N; Sharma S
    Future Oncol; 2021 Dec; 17(35):4925-4946. PubMed ID: 34672683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
    Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.